OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC lessened its stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,713 shares of the company's stock after selling 227,387 shares during the period. Bridgeway Capital Management LLC owned 0.16% of OptiNose worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Acorn Capital Advisors LLC purchased a new position in OptiNose in the fourth quarter valued at about $2,824,000. Institutional investors own 85.60% of the company's stock.

OptiNose Price Performance

NASDAQ OPTN traded up $0.02 during trading on Monday, hitting $9.71. The company's stock had a trading volume of 56,786 shares, compared to its average volume of 59,462. The company has a market cap of $98.33 million, a PE ratio of -2.31 and a beta of -0.88. The business's 50 day simple moving average is $8.89 and its 200-day simple moving average is $7.42. OptiNose, Inc. has a fifty-two week low of $4.82 and a fifty-two week high of $20.03.

OptiNose (NASDAQ:OPTN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.27). The business had revenue of $18.51 million during the quarter, compared to analyst estimates of $17.70 million. Analysts expect that OptiNose, Inc. will post -3.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares of the company's stock, valued at $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 8,213 shares of company stock valued at $43,643 over the last quarter. 2.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OPTN. Piper Sandler reiterated a "neutral" rating and issued a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st. HC Wainwright reissued a "neutral" rating and issued a $9.00 price target on shares of OptiNose in a report on Monday. Finally, Lake Street Capital downgraded OptiNose from a "buy" rating to a "hold" rating and lowered their price target for the stock from $17.00 to $9.00 in a report on Thursday, March 20th.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.